XFXiaocui Fang

Xiaocui Fang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaocui Fang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IMAN: An Integrated Colorimetric Sensor for Direct Detection of PD-L1 on Extracellular Vesicles in Lung Cancer Diagnosis

    by Jixuan Han, Shimeng He, Xinyue Liu, Ziyi Gao, Jiayu Xiao, Yuanhong Sun, Xiaocui Fang, Lilusi Ma, Chen Wang, Xuzhen Qin, et al.

    Lung cancer is a leading cause of cancer mortality, yet early diagnosis remains difficult, highlighting the need for sensitive, noninvasive methods. Extracellular vesicles (EVs) and their surface proteins (e.g., PD-L1) are promising biomarkers; nevertheless, current EV detection requires time-consuming purification, sophisticated instrumentation, and long measurement protocols, resulting in high expenses and operational difficulties. This study developed an integrated colorimetric sensor, IMAN, based on a strategy of “Immunomagnetic Microbeads (IM) capture + Aptamer(Apt) recognition + Nanozyme (N) catalysis”. IMAN employs magnetic beads modified with antibodies against CD9 and CD81 to directly capture EVs from serum, eliminating the need for time-consuming prior isolation; combined with a one-step colorimetric readout, the entire workflow can be completed with only ∼40 min of hands-on time, requiring no complex instrumentation. The PD-L1 protein on the EV surface is specifically recognized by a nanoparticle-bound nucleic acid aptamer. Signal generation is achieved through the catalytic oxidation of 3,3',5,5'-tetramethylbenzidine (TMB) by a platinum-gold bimetallic nanozyme (Pt@Au). The facile IMAN colorimetric method demonstrated a relatively broad dynamic range (107–1010 particles/mL), high specificity (unaffected by 100 pg/mL soluble PD-L1 in serum), and reproducibility (relative standard deviation, RSD = 9.1%). Analysis of clinical serum samples revealed significantly elevated EV-PD-L1 levels in patients with lung cancer compared with healthy donors and patients with benign nodule (p < 0.01). Receiver operating characteristic (ROC) analysis yielded areas under the curve (AUC) of 0.849 for distinguishing patients with lung cancer from healthy donors and 0.860 for distinguishing patients with lung cancer from patients with benign nodules, which are superior to those of the conventional serum biomarkers CEA and Cyfra21-1. By addressing the cost, complexity, and slow response of current methods, IMAN offers a simple, cost-effective platform for direct EV surface protein detection without complex instrumentation, providing a novel tool for the noninvasive lung cancer diagnosis.

  • A Dual-Action CXCR4-Targeted Peptide−Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppression in Pancreatic Cancer

    by Ke Zhu, Xuanxin Liu, Dapeng Li, Tao Wang, Tao Wen, Xiaocui Fang, Yanlian Yang, Jian Liu, Jie Meng, Chen Wang, et al.

    Gemcitabine (GEM) is a first-line therapeutic option for pancreatic cancer; however, it has low efficacy due to rapidly developed drug resistance and severe dose-limiting myelosuppression. To enhance its therapeutic effect, this study developed a novel peptide−drug conjugate using a CXCR4 antagonistic peptide as the targeting head and gemcitabine as the drug payload, based on the characteristics of pancreatic tumor cells highly expressing CXCR4 that mediates immunosuppression and tumor progression through interaction with its specific ligand CXCL12. The therapeutic effect of the conjugate (P12-GEM) was investigated using pancreatic ductal adenocarcinoma cell lines and an orthotopic pancreatic cancer mouse model. Its myelosuppressive effect was assessed from the perspective of hematological toxicity profiles. The results showed that P12-GEM maintained a cell-killing capability comparable to that of GEM while effectively inhibiting the phosphorylation of Erk and P38, thereby reducing CXCL12-mediated tumor cell migration and adhesion to stromal cells. In a tumor-bearing mouse model, P12-GEM demonstrated superior antitumor efficacy compared to GEM and significantly extended animal survival. Moreover, P12-GEM reduced the proportion of tumor-associated macrophages and increased the infiltration of CD8+ T cells in the tumor microenvironment without reducing platelet and white blood cell counts in the peripheral blood. In summary, P12-GEM possesses dual functions of CXCR4 antagonism and tumor cell killing, contributing to reversal of the immunosuppressive microenvironment and alleviation of myelotoxicity.

  • Multivalent Peptide-Guided EZH2 Degradation Sensitizes Immune Checkpoint Therapy in TNBC

    by Minxian Li, Haipeng Zhao, Lilusi Ma, Qiaojun Fang, Yanlian Yang, Wenfeng Zeng, Xiaocui Fang, Chen Wang

    Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Although an immune checkpoint blockade can reduce metastasis, its effectiveness is hindered by the immunosuppressive microenvironment in TNBC. EZH2 is overexpressed in TNBC, and patients with high EZH2 expression are associated with poor prognoses. The study developed EIP103 as a first-in-class peptide degrader that targets EZH2 through multivalent, high-affinity interactions and induces conformational destabilization, representing a mechanism distinct from that of the small molecule inhibitor EPZ-6438. The results demonstrated that EIP103 induces immunogenic cell death through lipid peroxidation, resulting in enhanced immune cell infiltration. Additionally, molecular dynamics (MD) simulations and biochemical assays revealed that the peptide EIP103 binds to the SET domain of EZH2, altering its structure and triggering proteasomal degradation via Praja Ring Finger Ubiquitin Ligase 2 (PJA2)-mediated ubiquitination. Harboring both enzymatic inhibition and post-translational regulation properties, EIP103 exerts durable efficacy and activates antitumor immunity, making it a promising therapeutic candidate for TNBC.


  • Targeted degradation of Pin1 by an antagonistic peptide enhances gemcitabine therapy in pancreatic cancer

    by Mengting Chen, Xiangyu Chu, Haipeng Zhao, Lilusi Ma, Jie Meng, Yanlian Yang, Qiaojun Fang, Xiaocui Fang, Chen Wang

    PIPWF peptide binds to the Pin1 protein through multi-site interactions, thereby inducing its conformational change and leading to subsequent degradation.


  • Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress via enhancing T cell responses and sensitizing cells to gemcitabine

    by Xin Huang, Hang Wu, Ke Zhu, Xuanxin Liu, Dapeng Li, Yuanhao Liu, Tao Wang, Tao Wen, Xiaocui Fang, Jian Liu, et al.

    CXCR4 antagonistic peptide, P12, prolongs the survival of pancreatic tumor bearing mice via inhibiting the phosphorylation of Erk and p38, sensitizing the tumor cells to gemcitabine, and enhancing the anti-tumor immune responses.


  • Open Access

    Poroptosis: A form of cell death depending on plasma membrane nanopores formation

    by Hao Li, Zihao Wang, Xiaocui Fang, Wenfeng Zeng, Yanlian Yang, Lingtao Jin, Xiuli Wei, Yan Qin, Chen Wang, Wei Liang


  • Enhancement of gold-nanocluster-mediated chemotherapeutic efficiency of cisplatin in lung cancer

    by Mei Jiang, Yuchen Lin, Xiaocui Fang, Mingpeng Liu, Lilusi Ma, Jingyi Liu, Mengting Chen, Yanlian Yang, Chen Wang

    A novel delivery system for cisplatin was constructed based on electrostatics-mediated assemblies of gold nanoclusters and PEGylated cationic peptide (cisplatin@GC-pKs). Encapsulated cisplatin in the as-formed micelle like assemblies was observed to demonstrate improved cellar uptake and enhanced chemotherapeutic efficiency in the cisplatin-resistant lung cancer cells. In vivo assays further confirmed that cisplatin@GC-pKs had profound anti-tumor efficiency due to deep penetration and accumulation of nanoscale cisplatin@GC-pKs via the enhanced permeability and retention (EPR) effect at tumor tissues. The constructed cisplatin@GC-pKs in this work demonstrated enhanced anti-tumor activity for lung cancer therapy, as well as a potential treatment strategy for a variety of cisplatin-resistance related malignancies.


  • Open Access

    Novel peptide-directed liposomes for targeted combination therapy of breast tumors

    by Kaiyue Zhang, Xiaocui Fang, Qing You, Yuchen Lin, Lilusi Ma, Shilin Xu, Yangyang Ge, Haiyan Xu, Yanlian Yang, Chen Wang

    PLipo-DOX–ICG demonstrates active targeting behavior for delivery and controllable release of chemotherapeutic drugs to CXCR4-overexpressing tumor ccells.


  • Open Access

    Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5

    by Xiaocui Fang, Hanyi Xie, Hongyang Duan, Ping Li, Maryam Yousaf, Haiyan Xu, Yanlian Yang, Chen Wang

    Cancer is the leading cause of death worldwide, and metastasis is the main attribute to cancer death. CXCR4 and its natural ligand CXCL12 have been known to play a critical role in tumorigenesis, angiogenesis and metastasis. Therefore, designing a new CXCR4 antagonist to prevent tumor metastasis will be of great significance. Herein, a novel chemically synthesized peptide (E5) that has an ability to target CXCR4/CXCL12 axis was loaded in micelle glycol-phosphatidylethanolamine (PEG-PE) block copolymer to form micelle-encapsulated E5 (M-E5). We demonstrated that M-E5 exhibited higher affinity for CXCR4-overexpressing MCF-7 and HepG2 tumor cells as compared to free E5, and efficiently inhibited the tumor cells migration. Mechanistic studies implied that PEG-PE micelle can encapsulate E5 and improve E5 targeting efficiency for CXCR4 by accumulating E5 on the tumor cell membrane. Furthermore, through encapsulation of chemotherapeutic drug doxorubicin (Dox) in PEG-PE micelle, we proved that PEG-PE micelle could serve as a co-carrier for both E5 and Dox (M-E5-Dox). M-E5 enhanced the efficiency of Dox by down-regulating the phosphorylation level of Akt, Erk and p38/MAPK proteins. In conclusion, PEG-PE micelle demonstrated a promising delivery system for E5, and M-E5 is expected to be a potential therapeutic agent that will help to improve the clinical benefits in current therapies used for solid tumors.